Founded in the Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical’s mission is to improve the health of millions of people worldwide through clinical research supported by global service delivery, world-class scientific leadership and therapeutic specialties.
Expertise
Click here to see our expertise by therapeutic area
George Clinical is a leading contract research organization (CRO), headquartered in Sydney, Australia, with more than 500 experienced people in 40 locations providing the full range of clinical trial services to pharmaceutical, medical device and diagnostic customers, for all trial phases, registration and post-marketing trials. George Clinical combines scientific and clinical leadership with expert trial delivery to create distinctive world-class solutions.
George Clinical’s partner in research, The George Institute for Global Health, is a leader in chronic disease research with a global network of experts with whom George Clinical engages. Together, this partnership enlists operationally-supported, internationally-recognized scientific leadership and an extensive series of investigator networks, which allows George Clinical to provide customizable, clinical trial excellence from trial design through all aspects of delivery.
As clinical trial costs and complexities escalate, our multi-disciplined experts provide customers with innovative solutions to access patient populations and reduce sponsor R&D costs, ensuring that their clinical trials have an impact for clinicians and patients, while maintaining the highest scientific integrity.
George Clinical’s partner in research, The George Institute (TGI) is established in Australia, affiliated with the University of Sydney and founded by Professors Stephen MacMahon and Robyn Norton, who serve as the organization’s Principal Directors.
The Institute for International Health, the predecessor of The George Institute for Global Health, is incorporated as a not-for-profit company.
The George Institute starts work in China. George Clinical is incorporated for the first time under the entity name iLifeData Pty. Ltd.
The George Institute begins its activities in India.
Trading name George Medica Pty Ltd is registered, and a center for research management is established within The George Institute to provide the staff, resources and expertise required to manage the growing portfolio of research projects within The Institute with optimal efficiency and appropriate quality.
The George Institute establishes an entity in India located in Hyderabad.
George Clinical is established by the George Institute as a separate contract research organization and commercialization arm to ensure its objectivity and to provide long-term financial sustainability. George Clinical gains a strong reputation for excellence in research and clinical trial management. All profits are given back to The George Institute to support its research endeavors. George Clinical is officially registered as the company’s business name.
George Clinical continues expansion in Asia by hiring staff in India and China under The George Institute organization but managed separately. George Clinical staff are hired in Malaysia.
George Clinical has grown seven-fold since its establishment almost a decade earlier under the name iLifeData Pty. Ltd. George Clinical has investigator contacts in 40 countries and over 300 sites.
George Clinical grows to a team of 150 employees in Australia, China, India and Asia, and works with partners to conduct global studies. George Clinical Asia-Pacific Ltd in Hong Kong, George Clinical India in Bengaluru and George Clinical Malaysia registered. George Clinical expands its remit to include respiratory disease, in particular, chronic obstructive pulmonary disease.
The team grows to 163 people, reflecting strong growth in China and East Asia. George Clinical establishes itself as a legal entity in China. George Clinical enters into two new formal partnerships with CROs based in Taiwan and South Korean. George Clinical is registered in New Zealand as a foreign company.
George Clinical continues to grow with new research hubs in the UK and Taiwan as well as business development operations in the USA. George Clinical establishes a new partnership in Japan to complement existing activities in India, China, Australia and East Asia. George Clinical (UK) Limited and George Clinical Taiwan are registered.
George Clinical South Korea registered, and total staff reaches 200.
George Clinical establishes partner office in Vietnam. George Clinical acquires Vector Oncology, and USA offices are located in Kansas City and Memphis.
George Clinical opens branches in the Philippines and Singapore to meet the growing demand for clinical trials in Asia. George Clinical is recognized with a major employer award in Hong Kong. Collaboration with the Heart Health Research Center further develops investigator networks.
Asia-Pacific capabilities strengthen with the award of a Taiwanese drug import license. George Clinical and EPSI, based in Japan, form a strategic partnership. George Clinical also establishes an entity in the Netherlands, providing a foothold for growing operations and business functions in Europe.
George Clinical forms a joint venture with Link-Health to form Link-George which will deliver clinical trials for Link Health and related companies as well as provide a one-stop service platform for in-licensing, clinical development, marketing authorization and commercialization.
Citeline names George Clinical a 2021 Award Finalist for Clinical Research Team of the Year as well as a Scrip Award 2021 Finalist for Best Full Service CRO of the Year. Frost & Sullivan recognizes the organization with the 2021 Asia-Pacific Competitive Strategy Leadership Award. George Clinical subscribes to the EcoVadis Sustainability Platform and is granted a Bronze Medal.
George Clinical expands European operations to include clinical research staff in Italy and Spain. Total staff exceeds 350.
The George Institute for Global Health
In 1999, The George Institute for Global Health was first founded in Australia with the aim of reducing the escalating burden of non-communicable diseases and injury around the world. Today it has grown to span more than 50 countries with 600 people across all global centers. The institute has raised almost $750 million for global health research to target the leading causes of death and disability worldwide. It is now ranked in the leading ten research institutions in the world for scientific impact. Click here to learn more.
George Clinical and EPS International Strategic Partnership
George Clinical and EPS International (EPSI) deliver service offerings in Asia-Pacific, the world’s most populous region, as well as worldwide for respective clients.
With this partnership, EPSI delivers clinical trial services for George Clinical clients in Japan; George Clinical provides clinical trial services for EPSI and its Japanese customers across Asia, the United States and Europe. In Asia, both companies provide a seamless operating capability for clinical trials across the Asia-Pacific region with the exception of China where both EPSI and George Clinical maintain an independent operating presence.
Since its establishment in 1991 as a pioneering CRO, EPS Group has been a healthcare solution provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, and academia with various solutions including development, marketing, sales, and consultation covering Asia centered in China. New value is currently being created in big data and AI, regenerative medicine, and more. The strength of EPSI lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas offices and has focused particularly on solidifying its sites in the respective Asian countries, providing clinical development support services as well as SMO services. Learn more about EPSI here and here.
